Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous CD34+ Stem Cell Therapy for CRVO
NCT03981549Phase 2Completed
- Sponsor
- Emmes
- Start
- Oct 2019
- Primary completion
- Nov 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of autologous bone marrow CD34+ stem cells in central retinal vein occlusion (CRVO) (2 arms), sponsored by Emmes. Primary endpoints: Incidence and Severity of Ocular and Systemic Adverse Events at 6 months and Feasibility of the Stem Cell Therapy at Day 182. Started Oct 2019; status: completed.
02
Drugs
autologous bone marrow CD34+ stem cells
03
Conditions
central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on NCT03981549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03981549.